


ABL Diagnostics Signs Exclusive Distribution Agreement with Riken Genesis to Expand Microbiology Genotyping in Japan

WOIPPY, FRANCE, March 17, 2025

/EINPresswire.com/ -- ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed leader in molecular diagnostics, is pleased to announce an exclusive distribution agreement with Riken Genesis Co., Ltd.

(<https://www.rikengenesis.jp/en.html>). Under this partnership, Riken Genesis will promote and commercialize ABLD’s DeepChek® and UltraGene molecular assays across laboratories in Japan, further strengthening its diagnostics portfolio.



Through this collaboration, Riken Genesis will offer an expanded range of real-time PCR assays (qPCR) (UltraGene), including syndromic testing panels (https://www.abldiagnostics.com/wp-content/uploads/2025/03/20250220_UltraGene_Assays_Brochure_v4.pdf). This agreement follows the recently announced licensing and transfer agreement of know-how and IP rights related to real-time polymerase chain reaction (PCR) tests made by ABL Diagnostics’ mother company, (<https://www.einpresswire.com/article/782808669/abl-inks-know-how-license-and-transfer-agreement-for-the-fast-track-diagnostics-pcr-portfolio-from-siemens-healthineers>), reinforcing Riken Genesis' position in molecular diagnostics.

Additionally, the exclusive distribution agreement includes the DeepChek® line of PCR assays and proprietary downstream analysis software systems, validated for use with both Capillary Electrophoresis (SANGER) and Next-Generation Sequencing (NGS) workflows.

“As a former distributor in Japan of the products related to the know-how acquired by ABL , we believe this new partnership with ABL Diagnostics will enable us to continue providing our customers with robust qPCR solutions that have a proven track record in Japan, while also incorporating advanced sequencing-based genotyping technologies for microbiology,” said Kenji Iwakabe, President and Chief Executive Officer of Riken Genesis .

Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics, added: “We are excited to collaborate with Riken Genesis to deliver state-of-the-art qPCR and genotyping solutions to microbiology laboratories in Japan.”

The syndromic multiplex testing market—which enables simultaneous detection of multiple pathogens—is projected to grow from USD 2.89 billion in 2025 to USD 4.17 billion by 2030, at a CAGR of 7.66% (<https://www.mordorintelligence.com/industry-reports/syndromic-multiplex-diagnostic-market>). With Japan’s strong research sector and growing demand for syndromic testing, this partnership presents significant growth opportunities.

The financial terms of the agreement remain undisclosed.

ABOUT ABL DIAGNOSTICS

ABL Diagnostics specializes in proprietary molecular biology assays and end-to-end solutions for precise molecular detection and genotyping:

- UltraGene – real-time PCR-based molecular detection.
- DeepChek® – DNA sequencing for genotyping.

Expanding Portfolio for Microbiology

Our growing portfolio covers:

- HIV diagnostics – Drug resistance assays, including a Whole Genome Kit.
- SARS-CoV-2, Tuberculosis, Hepatitis B & C – Advanced genotyping and drug resistance analysis
- Microbiome & Taxonomy – 16s/18s RNA-based analysis.
- Other viral & bacterial targets – Comprehensive molecular assays.

Syndromic & Digital Solutions

- Syndromic Real-Time PCR assays (known-how and IP acquired in 2025).
- Nadis® – EMR system used in 200+ hospitals in France for HIV & Hepatitis infected patients management.

-

ABL Diagnostics, based in Woippy, is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6). For further information, please visit www.abldiagnostics.com.

ABOUT RIKEN GENESIS

RIKEN GENESIS, founded in October 2007, provides lab-assay services as well as products for genetic testing based on cutting-edge gene analysis technologies and bioinformatics, and has experience in the field of personalized medicine. The company provides highly reliable tests based on international quality standards, as demonstrated by its CLIA certification, being the first organization in Japan to meet this U.S. quality control standard for clinical laboratories. For more information, please visit www.rikengenesis.jp

CONTACTS

ABL Diagnostics SA

72C route de Thionville - 57140 WOIPPY FRANCE

Tel : +33 (0)7 83 64 68 50

Email : info@abldiagnostics.com

<https://www.abldiagnostics.com>

RIKEN GENESIS CO. LTD.

1-2-2 Osaki, Shinagawa-ku

Tokyo, JAPAN Tel : +81 (03)57596041

Email : info2@rikengenesi.jp

<https://www.rikengenesi.jp/en.html>

Dr Sayada

ABL Diagnostics SA

+33 7 83 64 68 50

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/793484925>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.